Open a session
or
Create an account
Login
|
Français
Search
:
Advanced search
Hygienic Covers
HY21 Product line
Commode Chairs
Corporal Hygiene
Accessories
Kits
Protective Covers
View entire catalog
Login
I Require An Access Code
FAQ
Questions and comments
Contact us
About us
Your cart contains
0
product for a total of
CAD $0.00
Biophage Pharma highlights its strategy to address the rapidly increasing threat of MRSA infections
Tuesday, November 13, 2007
Phages to replace disinfectants in the fight against deadly bacteria
Montreal, November 12, 2007
- (TSX.V: BUG) - In response to recent investor interest in Biophage technologies and how we can address the rapidly increasing occurrences of life threatening MRSA (Methicillin-Resistant Staphylococcus Aureus) outbreaks in hospitals and schools across North America, the company is very pleased to provide an update on its development program.
MRSA infections are increasing at an alarming pace including in the community. The U.S. government estimates that MRSA sickens more than 90,000 people per year and is responsible for more deaths than AIDS. A recent review (Clinical Infectious Diseases, November 1 issue) reports that the number of infections increased over 7% each year from 1998 to 2003, while the economic burden to hospitals increased by nearly 12% annually (from $8.7 billion to $14.5 billion in 2003).
Biophage, working with its partners, in particular Hôpital Sacré-Coeur de Montréal and Hygie Canada, is currently evaluating phages against Staphylococcus, and particularly clinically active MRSA, to create a natural treatment to fight this harmful bacterial pathogen. These natural phages will be firstly used in liquid or in aerosol form for the decontamination of hospital wards and instruments. Different techniques for the production and delivery of concentrated and purified phage preparations are under investigation. This environmentally-friendly decontamination process will avoid or limit the use of harsh chemicals disinfectants and promise to revolutionize the current methods for cleaning and disinfecting hospital environments, schools, public restrooms or any high traffic areas.
Since the initial FDA GRAS approval of phage products in August 2006, Biophage technologies have gained market acceptance as an environmentally friendly and cost effective solution for bacterial decontamination. We have the technical knowledge and capability to bring phages from research to production: we can isolate, purify, characterize and produce commercial large scale volumes of phages for various applications. Along with our biosensors program (PDS® biosensors), we are developing an integrated solution to combat and control bacterial contamination.
"We are extremely excited by the market prospects for this new environmental friendly decontamination system based on natural phages to combat MRSA contamination in numerous environments." commented Dr. Rosemonde Mandeville, President and CEO. "The combination of our phage treatment and bacterial detection devices will provide an integrated way to combat bacterial contamination allowing rapid detection and decontamination processes to avoid outbreaks. We look forward to 2008 to push forward theses technologies and turn them into products for a healthier world. We would like to take this opportunity to warmly thank our investors for their continued support."
About Biophage Pharma Inc.
Biophage is a Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection, prevention and control of bacterial infections. Biophage operates three divisions: (1) The Therapeutics division for the prevention and control of bacterial contaminations in the medical, veterinary and environment fields; (2) The Biosensors division for the development and commercialization of PDS® Biosensors; both the Biosensor and Therapeutics programs have been structured to deliver an environmentally safe solution for the early detection and rapid control of deadly microorganisms; and (3) The Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, screening for Beryllium sensitization (the BeLPT test) and exclusive MELISA® for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten, pollens and more recently Lyme disease (Boreliosis). (
www.biophagepharma.net
;
www.immunotoxlabs.com
)
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts:
Biophage Pharma Inc.
Rosemonde Mandeville
, M.B., Ch.B., PhD.
President and CEO
(514) 496-1488
kEncEmailsptfnpoef/nboefwjmmfAcjpqibhfqibsnb/ofu
Louis Guindon
Chief Financial Officer
(514) 496-3230
kEncEmailmpvjt/hvjoepoAcjpqibhfqibsnb/ofu
« Back to news